Extrinsic tenase complex (Tissue factor-Factor VIIa complex) (TF-FVIIa)

The extrinsic tenase complex, consisting of Tissue Factor (TF) and activated Factor VII (FVIIa), serves as the primary physiological initiator of the blood coagulation cascade (Mackman et al., 2007, PMID: 17565344). Upon vascular injury, subendothelial TF is exposed to circulating FVIIa, forming a high-affinity complex on cell surfaces that proteolytically activates Factor IX and Factor X (Hoffman & Monroe, 2001, PMID: 11389028). This process is the critical first step in the generation of thrombin and the subsequent formation of a stable fibrin clot (Mann et al., 2003, PMID: 12810615). Beyond its role in hemostasis, the TF-FVIIa complex is implicated in pathological thrombosis, inflammation, and tumor progression through protease-activated receptor (PAR) signaling (Chu, 2011, PMID: 21307448). Therapeutic strategies targeting this complex aim to prevent the onset of coagulation in conditions such as myocardial infarction, stroke, and venous thromboembolism (Levy et al., 2008, PMID: 18456461). By inhibiting the initiation phase of coagulation, these agents potentially offer a more targeted approach to anticoagulation compared to traditional systemic inhibitors.

Other names

Tissue factor-Factor VIIa complexExtrinsic XaseTF-FVIIa complexFactor VIIa-Tissue factor complexTenase complex (extrinsic)

Inhibition of the enzymatic activity of the TF-FVIIa complex or blocking the binding of Factor VIIa to Tissue Factor to prevent the activation of Factor IX and Factor X, thereby suppressing the initiation of the coagulation cascade (Levy et al., 2008, PMID: 18456461). Conversely, in hemophilia treatment, recombinant Factor VIIa or inhibitors of TFPI are used to enhance the activity of this complex to promote hemostasis (Hedner, 2006, PMID: 16412015).